Allarity Therapeutics Past Earnings Performance
Past criteria checks 0/6
Allarity Therapeutics's earnings have been declining at an average annual rate of -35.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 57.6% per year.
Key information
-35.6%
Earnings growth rate
-62.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -57.6% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Allarity Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -20 | 9 | 7 |
| 31 Dec 22 | 0 | -21 | 10 | 7 |
| 30 Sep 22 | 0 | -35 | 14 | 16 |
| 30 Jun 22 | 0 | -29 | 15 | 14 |
| 31 Mar 22 | 0 | -28 | 14 | 14 |
| 31 Dec 21 | 0 | -27 | 12 | 14 |
| 30 Sep 21 | -1 | -12 | 4 | 9 |
| 30 Jun 21 | -1 | -12 | 3 | 8 |
| 31 Mar 21 | 0 | -7 | 3 | 5 |
| 31 Dec 20 | 0 | -7 | 4 | 4 |
| 30 Sep 20 | 1 | -16 | 8 | 0 |
| 30 Jun 20 | 1 | -17 | 7 | 0 |
| 31 Mar 20 | 0 | -20 | 5 | 0 |
| 31 Dec 19 | 0 | -20 | 3 | 0 |
| 30 Sep 19 | 0 | -11 | 2 | 0 |
| 30 Jun 19 | 1 | -8 | 2 | 0 |
| 31 Mar 19 | 1 | -4 | 2 | 0 |
| 31 Dec 18 | 1 | -2 | 1 | 0 |
| 30 Sep 18 | 2 | -1 | 1 | 0 |
| 30 Jun 18 | 1 | -1 | 1 | 0 |
| 31 Mar 18 | 2 | -4 | 3 | 0 |
| 31 Dec 17 | 1 | -5 | 3 | 0 |
| 30 Sep 17 | 1 | -6 | 3 | 0 |
| 30 Jun 17 | 1 | -6 | 3 | 0 |
| 31 Mar 17 | 0 | -4 | 0 | 0 |
| 31 Dec 16 | 0 | -4 | 0 | 0 |
| 30 Sep 16 | 1 | -3 | 0 | 0 |
| 30 Jun 16 | 1 | -2 | 0 | 0 |
| 31 Mar 16 | 1 | -2 | 0 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
Quality Earnings: C6D0 is currently unprofitable.
Growing Profit Margin: C6D0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: C6D0 is unprofitable, and losses have increased over the past 5 years at a rate of 35.6% per year.
Accelerating Growth: Unable to compare C6D0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: C6D0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: C6D0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.